| INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).BMC Cancer | PMID 36814222PMC9945618 | 2023-Feb-22 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).Medicine (Baltimore) | PMID 36827007PMC9949372 | 2023-Feb-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial.Neurology | PMID 36396451PMC9984220 | 2023-Feb-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial.JAMA | PMID 36809321PMC9945069 | 2023-Feb-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| BOHEMIA: Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug administration to reduce malaria transmission in two African settings.Trials | PMID 36810194PMC9942013 | 2023-Feb-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.J Clin Oncol | PMID 36327426PMC9937097 | 2023-Feb-20 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Mepitel Film for the Prevention of Acute Radiation Dermatitis in Breast Cancer: A Randomized Multicenter Open-Label Phase III Trial.J Clin Oncol | PMID 36493331无 PMCID | 2023-Feb-20 | 0.85 | This is a Phase III randomized trial in human oncology (breast cancer) with original results. However, it is excluded because the intervention (Mepitel Film) is not a drug (it's a silicone film/device for preventing radiation dermatitis), and the primary endpoint is not a time-to-event efficacy endpoint but an incidence rate of a toxicity (radiation dermatitis). No drug intervention or time-to-event endpoint is present. | 待处理 |
| Efficacy and safety of Obex® in overweight and obese subjects: a randomised, double-blind, placebo-controlled clinical trial.BMC Complement Med Ther | PMID 36804035PMC9940432 | 2023-Feb-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.J Clin Psychiatry | PMID 36811520无 PMCID | 2023-Feb-20 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.Lancet | PMID 36708734无 PMCID | 2023-Feb-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer.N Engl J Med | PMID 36791159无 PMCID | 2023-Feb-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.N Engl J Med | PMID 36791160无 PMCID | 2023-Feb-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.N Engl J Med | PMID 36791162PMC9947923 | 2023-Feb-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.Int J Cancer | PMID 36121651PMC10092493 | 2023-Feb-15 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study.J Med Internet Res | PMID 36790852PMC9978987 | 2023-Feb-15 | 0.95 | Study meets oncology, human, randomized, and phase criteria, but lacks required drug intervention and time-to-event endpoint; endpoint is pain intensity (VAS), not survival or progression. | 待处理 |
| Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.Neuro Oncol | PMID 35849035PMC9925712 | 2023-Feb-14 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.J Clin Oncol | PMID 36395435PMC9928683 | 2023-Feb-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.Vaccine | PMID 36681529无 PMCID | 2023-Feb-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.Br J Dermatol | PMID 36763857无 PMCID | 2023-Feb-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of downtitration or treatment withdrawal compared with continuous dosing after successful treatment with baricitinib in patients with moderate-to-severe atopic dermatitis in a randomized substudy from the long-term extension study BREEZE-AD3.Br J Dermatol | PMID 36763879无 PMCID | 2023-Feb-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer.N Engl J Med | PMID 36780674PMC10036605 | 2023-Feb-09 | 0.90 | The study is a Phase III randomized trial for human NSCLC with time-to-event endpoints (DFS, OS), but the intervention is surgical (sublobar resection vs lobar resection), not a drug-containing intervention. Drug intervention is a required criterion. | 待处理 |
| Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.Clin Infect Dis | PMID 35579509PMC9129191 | 2023-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate.Clin Infect Dis | PMID 35639602PMC9907483 | 2023-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Validation of a Health-Related Quality of Life Questionnaire in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial.Clin Infect Dis | PMID 35789381无 PMCID | 2023-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial.Clin Infect Dis | PMID 35906838PMC9384601 | 2023-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).Clin Infect Dis | PMID 36041016PMC10169427 | 2023-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.Clin Infect Dis | PMID 36164254PMC9907539 | 2023-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial.Clin Infect Dis | PMID 36210481PMC9619635 | 2023-Feb-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform.Radiat Oncol | PMID 36750848PMC9906937 | 2023-Feb-07 | 0.85 | The trial meets criteria for oncology, human, randomized, phase III, time-to-event endpoints, and original results, but it lacks the required drug-containing intervention. The comparison is between two radiation delivery technologies, not a drug. | 待处理 |
| PARa-aOrtic LymphAdenectomy in locally advanced cervical cancer (PAROLA trial): a GINECO, ENGOT, and GCIG study.Int J Gynecol Cancer | PMID 36717163无 PMCID | 2023-Feb-06 | 0.95 | The study is a randomized Phase III trial in human oncology with a time-to-event primary endpoint, but it does not describe a drug-containing intervention (it is a surgical and radiotherapy-based trial). Furthermore, it is a protocol abstract, not a report of original results. | 待处理 |
| Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial.BMJ | PMID 36746459PMC9900470 | 2023-Feb-06 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized double-blind, placebo-controlled study of oral gabapentin for prevention of neuropathy in patients receiving paclitaxel.Trials | PMID 36732774PMC9896696 | 2023-Feb-03 | 0.85 | The record is a protocol for a Phase III randomized trial investigating a drug intervention for neuropathy prevention in cancer patients. However, it is not an original result report, and its primary endpoint is not a time-to-event oncology efficacy endpoint. | 待处理 |
| VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.N Engl J Med | PMID 36577095PMC9812289 | 2023-Feb-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.J Clin Oncol | PMID 36219809PMC9902012 | 2023-Feb-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.J Clin Oncol | PMID 36332161无 PMCID | 2023-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.JAMA Oncol | PMID 36416836PMC9685550 | 2023-Feb-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).JAMA Dermatol | PMID 36630140PMC9857439 | 2023-Feb-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.JAMA Netw Open | PMID 36753281PMC9909498 | 2023-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial.JAMA Netw Open | PMID 36826820PMC9958529 | 2023-Feb-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria.Pediatr Nephrol | PMID 35552824PMC9763141 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk.Acta Pharmacol Sin | PMID 35896694PMC9889741 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Opium tincture versus methadone for opioid agonist treatment: a randomized controlled trial.Addiction | PMID 35971297无 PMCID | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.Eur Radiol | PMID 35976398PMC9889429 | 2023-Feb | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.Cancer Med | PMID 36052536PMC9939146 | 2023-Feb | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.Cancer Med | PMID 36052772PMC9939192 | 2023-Feb | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.Clin Microbiol Infect | PMID 36096430PMC9463077 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.Ann Rheum Dis | PMID 36100350PMC9887347 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.Hypertens Res | PMID 36100672PMC9899688 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Inclusion of patients with chronic kidney disease in randomized phase 3 clinical trials in patients with prostate, breast, lung, and colorectal cancer.Cancer Med | PMID 36156460PMC9939176 | 2023-Feb | 0.95 | This record is a methodological analysis of patient exclusion criteria across multiple phase 3 oncology trials, not a report of survival or efficacy outcomes from a specific randomized controlled trial. While the publication metadata indicates it is a Phase III/Randomized Controlled Trial journal article, the content is a survey of trial protocols (ClinicalTrials.gov) focusing on renal exclusion criteria, not trial results. It therefore lacks the required outcome signal (survival, progression, etc.) for inclusion. | 待处理 |
| Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).Diabetes Obes Metab | PMID 36184780PMC10092154 | 2023-Feb | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |